Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical Treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaçi*, Eric L. Simpson, Lisa A. Beck, Thomas Bieber, Andrew Blauvelt, Kim Papp, Weily Soong, Margitta Worm, Jacek C. Szepietowski, Howard Sofen, Makoto Kawashima, Richard Wu, Steven P. Weinstein, Neil M.H. Graham, Gianluca Pirozzi, Ariel Teper, E. Rand Sutherland, Vera Mastey, Neil Stahl, George D. Yancopoulos
*Korrespondierende/r Autor/-in für diese Arbeit
- Oregon Health & Science University
- University of Rochester Medical Center
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Oregon Medical Research Center
- Probity Medical Research
- Alabama Allergy and Asthma Center
- Charite - Universitatsmedizin Berlin
- Wroclaw Medical University
- David Geffen School of Medicine at UCLA
- Tokyo Women's Medical University
- Regeneron Pharmaceuticals, Inc.
- Sanofi S.A.
- Sanofi
540
Link öffnet neuen Tab
Zitate (Scopus)